(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol

Hypercholesterolemia Clinical Trial

— FUTURA  

Official title:

Randomized Multicenter Crossover Study to Compare the Plasmat® Futura Heparin Induced Extracorporeal Lower Density Lipo-Protein (LDL) Precipitation (H.E.L.P.) Apheresis System to the Approved Secura System in the Reduction of LDL-c in Patients With Hypercholesterolemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00526058
• Other study ID #: LDLc-A-US2-0406
• Status: Completed
• Phase: N/A
• Start date: August 2007
• Est. completion date: December 2008

Study information

• Verified date: August 2018
• Source: B. Braun Medical Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to demonstrate that the performance of the modified Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved Plasmat® Secura H.E.L.P Apheresis System for use under the approved indication of the acute reduction of LDL-cholesterol from the plasma in populations for whom diet has been ineffective and maximum drug therapy has either been ineffective or not tolerated.

Description:

The primary study endpoint is the change in percent measurements of the pre-to-post apheresis LDL measurements between the approved H.E.L.P. system and the modified H.E.L.P. system. The secondary study endpoints are clinical lab profiles and device parameters analyzed at specific time points throughout the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: December 2008
• Est. primary completion date: October 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 70 Years

Eligibility

Inclusion Criteria:

• Subject is between 25 and 70 years of age (inclusive) at the time of randomization.

• Subject is an appropriate candidate for H.E.L.P. apheresis treatment for hypercholesterolemia according to current Plasmat® Secura approval criteria.

• Subject has received a minimum of two consecutive bi-monthly* H.E.L.P. apheresis treatments using the Plasmat® Secura apheresis system >30 days prior to the screening visit.

• Subject is willing to maintain cholesterol lowering dietary and drug therapies as prescribed through the course of the study.

• Subject is willing and able to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) Waiver.

• Sterile, post-menopausal, or using acceptable birth control for the duration of the study. Acceptable birth control is defined as having a vasectomized, postmenopausal, or sterile partner; the ongoing use of approved hormonal contraceptives, barrier method, or an intrauterine device; or abstinence.

• Every 14 days (±2 days)

Exclusion Criteria:

• A History of a known sensitivity to heparin or ethylene oxide.

• A history of hemorrhagic diathesis, bleeding/clotting disorder, thrombocytopenia (defined as platelet count < 150 x109/L), or for whom the use of heparin would cause excessive or uncontrolled anticoagulation or for whom adequate anticoagulation cannot be safely achieved (ie., hemophilia, recent surgery, acute internal bleeding, gastrointestinal ulcers).

• Females who are pregnant or lactating.

• Subjects< 106 lbs. or <48.2 kg in body weight; or whose weight is >1.5 times their ideal weight.

• Certain cardiac impairments such as congestive heart failure, major arrhythmia, or diastolic blood pressure greater than 100 mm/Hg on two separate occasions at least 24 hours apart.

• Renal insufficiency defined as creatinine greater >2.0 mg/dlL or is dependent upon renal dialysis.

• Untreated hypothyroidism; uncontrolled diabetes mellitus; or fasting triglycerides >500 mg/dL.

• Serious systemic disease (e.g., advanced neoplasms, and acute hepatitis) including Immune system suppression or compromise, that could preclude survival to study completion.

• History of stroke within 6 months of the screening visit.

• Received thrombolytic treatment < 7 days of screening.visit.

• Taken or requires a prohibited treatment < 30 days prior to the Screening Visit, or requires a prohibited treatment at anytime during the course of the study.

• Neutropenia (neutrophil count < 0.5 x109/L).

• History of liver disease or serum ALT and/or AST > 2X upper limit of normal range.

• History of dementia.

• History of anemia (value outside the lower normal range).

• acetyl salicylic acid (ASA) > 325 mg/day.

• Subject currently enrolled in another investigational study (does not apply to PMS for Secura device).

• Subject with any other medical condition that in the opinion of the investigator might put the subject at risk or interfere with his/her participation.

• Subject is unwilling or unable to comply with the protocol or to cooperate fully with the investigator or site personnel.

Related Conditions & MeSH terms

• Hypercholesterolemia

Intervention

Device:
• Secura then Futura
Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.
• Futura then Secura
Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.

Locations

Country	Name	City	State
United States	Hartford Hospital	Hartford	Connecticut
United States	University of Kansas Medical Center	Kansas City	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
B. Braun Medical Inc.

Country where clinical trial is conducted

United States, 

References & Publications (4)

Julius U, Metzler W, Pietzsch J, Fassbender T, Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int J Artif Organs. 2002 Dec;25(12):1180-8. — View Citation

Moriarty PM, Gibson CA, Shih J, Matias MS. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis. 2001 Oct;158(2):495-8. — View Citation

Schettler V, Monazahian M, Wieland E, Thomssen R, Müller GA. Effect of heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) apheresis on hepatitis C plasma virus load. Ther Apher. 2001 Oct;5(5):384-6. — View Citation

Susca M. Heparin-Induced extracorporeal low-density lipoprotein precipitation futura, a new modification of HELP apheresis: technique and first clinical results. Ther Apher. 2001 Oct;5(5):387-93. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change in Pre- and Post-treatment Reductions of Low-density Lipoprotein Cholesterol (LDL-C) Levels Between the Approved H.E.L.P. System and the Modified H.E.L.P. System.		Blood samples for LDL-cholesterol determination will be obtained before and after each treatment from week 0 to week 24..
Primary	Percent Change of the Pre and Post Treatment Value	The primary study endpoint is the change in percent measurements of the pre-to-post apheresis LDL measurements. Blood samples for LDL-cholesterol determination will be obtained before and after each treatment. The pooled difference between the pre- and post-treatment LDL level for each apheresis machine will be reported as the primary endpoint for the system performance.	Assessment based on LDL-C values obtained pre-and post-treatment, analyzed from week 0 to week 24.
Secondary	Clinical Lab Profiles (Pre- and Post-Treatment)	Changes in pre- and post-treatment levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), total triglycerides, lipoprotein (a), fibrinogen, and C-reactive protein.	Analyzed at specific time points throughout the study from week 0 to week 24.
Secondary	Device Parameters	Comparison of plasma flow rate recorded with both systems before treatment, after 500 mL of plasma treated, and at the end of each treatment session.	Analyzed at specific time points throughout the study from week 0 to week 24.